- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Julie Maréchal-Jamil: Biosimilar Education in Europe
Julie Maréchal-Jamil, director of biosimilars policy and science at Medicines for Europe, describes current educational needs around biosimilars.
Transcript
In the EU, we've been on the educational journey for now 13 years, and if we look at the situation, we have a pretty rich base of documentation, communication materials. What I think has been a game-changer in the educational aspect is when the government institutions, authorities have stepped in and realized that they needed to tailor information.
We started with a general document in 2013 which was developed in a multistakeholder fashion. Then we also collectively looked at having dedicated patient materials and the healthcare professional [European Medicines Agency, EMA] document last year.
All of that together, we are answering the availability of documentation, the legitimacy of the source, which is extremely important. We’ve also tackled the suitability of the language used, the level for the user.
What remains to be done, you may have seen in the last days, is maybe there's still a different level of understanding between the European levels, be it organizations like patient groups, industrial groups, and maybe what happens at the national level. Another barrier is the language, not in terms of suitability, but in terms of simply English, Spanish, Romanian, or other languages, which actually can be a very important hurdle for local acceptance and growth in confidence.
So in terms of education, I think there's still a lot going on, but it will be more in the dissemination and into empowering local actors.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
